Drug Trial Radar · NCT07860554
Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); Novartis
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has continued to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production (castration-resistant). Pluvicto is a targeted radioligand therapy. It works like a guided missile, combining tumor seeking molecules with a radioactive isotope. It circulates through the bloodstream, binds to a protein on prostate cancer cells called prostate specific membrane antigen, and destroys them using radiation. Pluvicto is approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. This trial may help researchers determine the safety and efficacy of Pluvicto specifically in African American patients with metastatic castration-resistant prostate cancer.
Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Bone ScanProcedure
Undergo bone scan
Computed TomographyProcedure
Undergo CT
Lutetium Lu 177 Vipivotide TetraxetanDrug
Given IV
PSMA PET ScanProcedure
Undergo PSMA PET scan
Questionnaire AdministrationOther
Ancillary studies
Single Photon Emission Computed TomographyProcedure
Undergo SPECT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic progression-free survival (rPFS)Time frame: From the start of study treatment to the first objective documentation of radiographic disease progression or death, assessed up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.